Immix Biopharma, Inc. (IMMX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Los Angeles, CA, United States. The current CEO is Graham Ross.
IMMX has IPO date of 2021-12-16, 18 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $521.7M.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
